Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 9:32 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 1,452 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Primary Parkinsonism Clear all

Conditions: Parkinson's Disease, Essential Tremor, Dystonia, Obsessive Compulsive Disorder
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2025
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Parkinson's Disease
Interventions: GUIDE software, Version 0.1, Clinically defined stimulation parameters; Device
Lead sponsor: Intelect Medical, Inc.; Industry
Eligibility: Not listed
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 4
States / cities: Gainesville, Florida • Manhasset, New York • Kirkland, Washington + 1 more

Conditions: Idiopathic Parkinson's Disease
Interventions: Istradefylline 40 mg, Istradefylline 20 mg, Placebo; Drug
Lead sponsor: Kyowa Kirin Co., Ltd.; Industry
Eligibility: 30 Years and older
Enrollment: 613 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 41
States / cities: Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 36 more

Conditions: Parkinson's Disease
Interventions: Not listed
Lead sponsor: University of Michigan; Other
Eligibility: 50 Years and older
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Parkinson's Disease
Interventions: IPX066; Drug
Lead sponsor: Impax Laboratories, LLC; Industry
Eligibility: 30 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 8
States / cities: Birmingham, Alabama • La Jolla, California • Sunnyvale, California + 5 more

Conditions: Parkinson's Disease
Interventions: Oxaloacetate (OAA), Placebo; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 30 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
Interventions: Not listed
Lead sponsor: Sanguine Biosciences; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 17,667 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Parkinson's Disease
Interventions: KHV reporting, Standard care; Device · Procedure
Lead sponsor: Great Lakes NeuroTechnologies Inc.; Industry
Eligibility: Not listed
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Parkinson's Disease
Interventions: NS2330, Levodopa and Domperidone; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Parkinson Disease
Interventions: Not listed
Lead sponsor: BlueRock Therapeutics; Industry
Eligibility: 50 Years to 78 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Orange, California • New York, New York

Conditions: Parkinson's Disease
Interventions: Activa PC+S; Device
Lead sponsor: Colorado Neurological Institute; Other
Eligibility: 21 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Englewood, Colorado

Conditions: Parkinson Disease, Parkinson Disease, Idiopathic
Interventions: Community Walking Program; Behavioral
Lead sponsor: St. Louis University; Other
Eligibility: 30 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Parkinson's Disease
Interventions: Non-traditional group guitar instruction; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Parkinson Disease
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 40 Years to 85 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Parkinson Disease
Interventions: CoQ10, GPI 1485; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 30 Years and older
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Parkinson's Disease
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: 50 Years to 90 Years
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2021
U.S. locations: 3
States / cities: La Jolla, California • Chicago, Illinois • New York, New York

Conditions: Parkinson's Disease
Interventions: Dynacirc CR (Isradipine); Drug
Lead sponsor: Northwestern University; Other
Eligibility: 30 Years to 75 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Parkinson's Disease, Perception, Visual Hallucination
Interventions: Not listed
Lead sponsor: Boston University Charles River Campus; Other
Eligibility: 40 Years to 110 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Autonomic Failure, Pure Autonomic Failure, Parkinson Disease, Multiple System Atrophy, Dementia With Lewy Bodies
Interventions: [18F]FDOPA, Carbidopa 200mg oral dose, Entacapone 400mg oral dose; Drug
Lead sponsor: Daniel Claassen; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Parkinson Disease, Anxiety, Depression
Interventions: Mindfulness-based cognitive therapy (MBCT); Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Parkinson Disease
Interventions: NS 2330; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 47
States / cities: Peoria, Arizona • Tucson, Arizona • Fountain Valley, California + 38 more

Conditions: Parkinson Disease
Interventions: High intensity endurance exercise, Stretching exercise, Virtual reality (VR)-based gaming; Behavioral
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 85 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Parkinson Disease
Interventions: sumanirole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 30 Years and older
Enrollment: 984 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 103
States / cities: Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 100 more

Conditions: Dyskinesia, Levodopa-Induced Dyskinesia (LID), Parkinson's Disease (PD)
Interventions: ADS-5102, Placebo; Drug · Other
Lead sponsor: Adamas Pharmaceuticals, Inc.; Industry
Eligibility: 30 Years to 85 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 21
States / cities: Fountain Valley, California • Sunnyvale, California • Boca Raton, Florida + 18 more

Search by objective public record fields.

Sensory Gating Measured With Microelectrode Recording (MER) During Deep Brain Stimulation (DBS) Surgery

Feasibility Study to Evaluate Deep Brain Stimulation (DBS) Settings for the Treatment of Parkinson's Disease

A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease

Cholinergic Nicotinic Receptors and Cognition in PD

Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study

A Pilot Study of Oxaloacetate in Subjects With Treated PD

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions

Automated Telehealth Diagnostics for Remote Parkinson Monitoring

Effects of Monoamine Reuptake Inhibitor NS2330 in Parkinson's Disease

Continued Evaluation of Patients With Parkinson's Disease Who Previously Received BRT-DA01

LFP Correlates of Movement Disorders

Step Up to PD: A Community-based Walking Program for People With Parkinson's Disease

Impact of Non-traditional Guitar Group Instruction on Functional Movement and Well-being in Parkinson's Disease Patients

Relationship of Dopamine to Cognitive Function in Parkinson's Disease

NINDS Parkinson's Disease Neuroprotection Trial of CoQ10 and GPI 1485

Antigen Presentation and Lymphocyte Response in Parkinson's Disease

Parkinson's Disease Isradipine Safety Study

Perception in Parkinson's Disease

[18F]F-DOPA Imaging in Patients With Autonomic Failure

Mindfulness-based Cognitive Therapy (MBCT) for People With Parkinson's Disease

A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)

Endurance Exercise & Virtual Reality for Optimizing Cortical Excitability and Neuroplasticity in PD

Open Label Sumanirole Study of Safety, Tolerability, and Therapeutic Response In Patients With Parkinson's Disease

Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia